227 related articles for article (PubMed ID: 36181774)
1. The MDMX Acidic Domain Uses Allovalency to Bind Both p53 and MDMX.
Fenton M; Borcherds W; Chen L; Anbanandam A; Levy R; Chen J; Daughdrill G
J Mol Biol; 2022 Nov; 434(22):167844. PubMed ID: 36181774
[TBL] [Abstract][Full Text] [Related]
2. Autoinhibition of MDMX by intramolecular p53 mimicry.
Chen L; Borcherds W; Wu S; Becker A; Schonbrunn E; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4624-9. PubMed ID: 25825738
[TBL] [Abstract][Full Text] [Related]
3. MDMX acidic domain inhibits p53 DNA binding in vivo and regulates tumorigenesis.
Huang Q; Chen L; Yang L; Xie X; Gan L; Cleveland JL; Chen J
Proc Natl Acad Sci U S A; 2018 Apr; 115(15):E3368-E3377. PubMed ID: 29581299
[TBL] [Abstract][Full Text] [Related]
4. The MDMX acidic domain competes with the p53 transactivation domain for MDM2 N-terminal domain binding.
Song Q; Liu XQ; Rainey JK
Biochim Biophys Acta Mol Cell Res; 2022 Oct; 1869(10):119319. PubMed ID: 35780910
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
6.
Song Q; Liu XQ; Rainey JK
Biomol NMR Assign; 2022 Apr; 16(1):171-178. PubMed ID: 35359247
[TBL] [Abstract][Full Text] [Related]
7. Optimal Affinity Enhancement by a Conserved Flexible Linker Controls p53 Mimicry in MdmX.
Borcherds W; Becker A; Chen L; Chen J; Chemes LB; Daughdrill GW
Biophys J; 2017 May; 112(10):2038-2042. PubMed ID: 28487147
[TBL] [Abstract][Full Text] [Related]
8. Competitive binding between dynamic p53 transactivation subdomains to human MDM2 protein: implications for regulating the p53·MDM2/MDMX interaction.
Shan B; Li DW; Brüschweiler-Li L; Brüschweiler R
J Biol Chem; 2012 Aug; 287(36):30376-84. PubMed ID: 22807444
[TBL] [Abstract][Full Text] [Related]
9. Targeting the conformational transitions of MDM2 and MDMX: insights into key residues affecting p53 recognition.
Carotti A; Macchiarulo A; Giacchè N; Pellicciari R
Proteins; 2009 Nov; 77(3):524-35. PubMed ID: 19507240
[TBL] [Abstract][Full Text] [Related]
10. Casein kinase 1α regulates an MDMX intramolecular interaction to stimulate p53 binding.
Wu S; Chen L; Becker A; Schonbrunn E; Chen J
Mol Cell Biol; 2012 Dec; 32(23):4821-32. PubMed ID: 23028042
[TBL] [Abstract][Full Text] [Related]
11. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
[TBL] [Abstract][Full Text] [Related]
12. Calculation of hot spots for protein-protein interaction in p53/PMI-MDM2/MDMX complexes.
Huang D; Qi Y; Song J; Zhang JZH
J Comput Chem; 2019 Apr; 40(9):1045-1056. PubMed ID: 30549062
[TBL] [Abstract][Full Text] [Related]
13. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
14. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
15. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
[TBL] [Abstract][Full Text] [Related]
16. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis for the inhibition of p53 by Mdmx.
Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
[TBL] [Abstract][Full Text] [Related]
18. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
[TBL] [Abstract][Full Text] [Related]
19. A site-directed mutagenesis study of the MdmX RING domain.
Egorova O; Mis M; Sheng Y
Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
[TBL] [Abstract][Full Text] [Related]
20. Secondary interaction between MDMX and p53 core domain inhibits p53 DNA binding.
Wei X; Wu S; Song T; Chen L; Gao M; Borcherds W; Daughdrill GW; Chen J
Proc Natl Acad Sci U S A; 2016 May; 113(19):E2558-63. PubMed ID: 27114532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
